Mydecine Innovations Group (MYCOF) Stock Price, News & Analysis

Company Overview

Mydecine Innovations Group Inc. is a biotechnology company focused on developing psychedelic-derived therapies for mental health and neurological conditions. Its research has centered primarily on psilocybin-based treatments intended to address conditions such as post-traumatic stress disorder, depression, and substance-use disorders.

The company has pursued the discovery, development, and clinical evaluation of novel psychedelic compounds and treatment protocols. Its activities have included pharmaceutical formulation, preclinical research, and collaborations with academic and clinical institutions to investigate the safety, effectiveness, and potential therapeutic applications of psychedelic medicines.

Mydecine was established in the early 2020s and has focused much of its research and development in North America, including work involving veteran and other patient populations. The company’s programs and corporate structure have evolved over time, and publicly available information about its current product pipeline and leadership may be limited.

Key Stats

• Today's Range: $0.73 to $0.73
• 50-Day Range: $0.73 to $0.73
• 52-Week Range: $0.01 to $2.04
• Volume: N/A
• Average Volume: 3,650 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/16/2021
• Today: 10/16/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:MYCOF
• CIK: N/A
• Web: www.newleafbrands.com
• Phone: (604) 687-2038
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A